Professional summary
Dr Singer is a pollution scientist with research interests focused on understanding its effects on microbial ecology, ecosystem function and human health. Singer's research frequently has a policy-relevance angle, such as characterising the nature and effects of large-scale pharmaceutical use (e.g., antivirals such as Tamiflu, and antibiotics), during an influenza pandemic (1,2,3,4,5), and the drivers of antibiotic (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11) and antifungal (1, 2, 3) resistance in the environment and their implications to ecosystems and human health (1, 2, 3, 4), especially during a pandemic (1). His research includes national (1, 2) and international studies (1, 2, 3, 4) on the environmental drivers of AMR, their relevance to human health and considerations for policy makers (1, 2, 3, 4, 5). Dr Singer is active in the field of wastewater pollution (1, 2, 3) and epidemiology (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13), which aims to understand human behaviour and health through the analysis of sewage, e.g., pathogen incidence and prevalence, drug compliance. He also actively participates in the debate over the funding models needed for reinvigorating the novel antibiotic pipeline (1, 2, 3).
Dr Singer is on the One Health Priority Research Agenda on AMR Quadripartite Technical Core team; the FWR Sustainable Wastewater Management Technical Panel; and previously served on the National Engineering Policy Centre/Royal Academy of Engineering commissioned “Wastewater & Public Health Working Group”, led by the Chief Medical Officer, Prof Sir Chris Whitty. Dr Singer received a PhD in Soil and Water Science, from the University of California (2000), Riverside and a BA in Anthropology from the University of California, Berkeley. (1992).
Dr Singer has been professionally active in the arts for over two years. He has: 1) co-written a play with a professional theatre director and writer; 2) worked with multiple professional dramaturgs to refine the critically aclaimed (5*) science-themed play: Panacea (1) which follows on from the first run of the play, which was also well-received (1); 3) served as Executive Producer and stage manager for three runs of Panacea in London; 4) secured funding and Executive Produced a tour of Panacea in London, Birmingham and Liverpool; and 4) is currently writing two sequels to Panacea (II & III). He seeks further opportunities to merge theatre and science, to share the challenges of academia and science with the public, inclusive of the science and the associated ethics.